Serum secreted frizzled‑related protein 5 levels differentially decrease in patients with hepatitis B virus‑associated chronic infection and hepatocellular carcinoma

Peng,Chuan; Xiao,Xiaoqiu; Kang,Bing; He,Song; Li,Jibin

doi:10.3892/ol.2014.2256

Serum secreted frizzled‑related protein 5 levels differentially decrease in patients with hepatitis B virus‑associated chronic infection and hepatocellular carcinoma

Authors:
- Chuan Peng
- Xiaoqiu Xiao
- Bing Kang
- Song He
- Jibin Li
View Affiliations

Affiliations: Department of Nutrition and Food Hygiene, School of Public Health and Management, Chongqing Medical University, Chongqing 400016, P.R. China, Laboratory of Lipid and Glucose Metabolism, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China
Published online on: June 16, 2014 https://doi.org/10.3892/ol.2014.2256
Pages: 1340-1344

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the characteristics of serum secreted frizzled‑related protein 5 (SFRP5), an inhibitor of Wnt signaling, in hepatitis B virus (HBV)‑associated infections and hepatocellular carcinoma (HCC) patients. Serum SFRP5 levels were detected in 147 patients with HBV‑associated chronic infection or HCC. Compared with the non‑HBV‑infected and non‑HCC group, the HBV‑associated chronic infection and HCC groups exhibited decreased serum SFRP5 levels. A significant inverse correlation between serum SFRP5 levels and HBV DNA levels was identified in the HBV‑associated chronic infection and HCC groups. Furthermore, SFRP5 levels differentially decreased in patients with HBV‑associated diseases, in a manner which was dependent on liver disease status. Compared with patients exhibiting HBV‑associated chronic infection, patients with HCC were found to exhibit lower serum SFRP5 levels. The results of the present study indicated that patients with HBV‑associated liver infection and HCC exhibited significantly deceased serum SFRP5 levels, which were found to negatively correlate with HBV DNA levels. Serum SFRP5 levels may present a biomarker for the severity of HBV‑associated liver infection, and the risk of HCC initiation and progression.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
3	Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 15(Suppl 4): S5–S13. 2010.
4	Zhu AX, Chabner BA and Tanabe KK: New trends and novel treatment for hepatocellular carcinoma: a global perspective. Oncologist. 15(Suppl 4): S1–S4. 2010.
5	Bengochea A, de Souza MM, Lefrançois L, et al: Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 99:143–150. 2008.
6	Camilli TC and Weeraratna AT: Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression. Biochem Pharmacol. 80:702–711. 2010.
7	Liu H, Fergusson MM, Wu JJ, et al: Wnt signaling regulates hepatic metabolism. Sci Signal. 4:ra62011.
8	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009.
9	Uematsu K, He B, You L, Xu Z, McCormick F and Jablons DM: Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 22:7218–7221. 2003.
10	Segditsas S and Tomlinson I: Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 25:7531–7537. 2006.
11	Urakami S, Shiina H, Enokida H, et al: Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 12:2109–2116. 2006.
12	Thompson MD and Monga SP: WNT/beta-catenin signaling in liver health and disease. Hepatology. 45:1298–1305. 2007.
13	Yook JI, Li XY, Ota I, et al: A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 8:1398–1406. 2006.
14	Bovolenta P, Esteve P, Ruiz JM, Cisneros E and Lopez-Rios J: Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci. 121:737–746. 2008.
15	Marsit CJ, Karagas MR, Andrew A, et al: Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 65:7081–7085. 2005.
16	Nojima M, Suzuki H, Toyota M, et al: Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene. 26:4699–4713. 2007.
17	Takagi H, Sasaki S, Suzuki H, et al: Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol. 43:378–389. 2008.
18	Kawakami K, Yamamura S, Hirata H, et al: Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer. Int J Cancer. 128:541–550. 2011.
19	Shepard CW, Simard EP, Finelli L, Fiore AE and Bell BP: Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 28:112–125. 2006.
20	Capurro MI, Xiang YY, Lobe C and Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254. 2005.
21	Lee HC, Kim M and Wands JR: Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci. 11:1901–1915. 2006.
22	Bovolenta P, Rodriguez J and Esteve P: Frizzled/RYK mediated signalling in axon guidance. Development. 133:4399–4408. 2006.
23	Cheng YY, Yu J, Wong YP, et al: Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer. 97:895–901. 2007.
24	Suzuki H, Gabrielson E, Chen W, et al: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 31:141–149. 2002.
25	Suzuki H, Watkins DN, Jair KW, et al: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 36:417–422. 2004.
26	Quan H, Zhou F, Nie D, et al: Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene. 2013.
27	Fukui T, Kondo M, Ito G, et al: Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene. 24:6323–6327. 2005.
28	Shih YL, Shyu RY, Hsieh CB, et al: Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 107:579–590. 2006.
29	Park IY, Sohn BH, Yu E, et al: Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology. 132:1476–1494. 2007.
30	Sasaki Y: Does oxidative stress participate in the development of hepatocellular carcinoma? J Gastroenterol. 41:1135–1148. 2006.
31	Tong A, Gou L, Lau QC, et al: Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J Proteome Res. 8:1037–1046. 2009.
32	Zhao C, Bu X, Zhang N and Wang W: Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer. BMC Cancer. 9:2242009.